Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Introducing the Contract Pharma 'Friday Brief' — April 10, 2026 | Contract Pharma

What are you searching for?

Sign in
Friday Brief, Videos

Introducing the Contract Pharma ‘Friday Brief’ — April 10, 2026

Author Image

By: Patrick Lavery

Content Marketing Editor

A new feature is debuting on the Contract Pharma website: “The Friday Brief,” hosted by Content Marketing Editor Patrick Lavery. This video will drop every Friday morning, and serve as a week-in-review of some of our best coverage. Let’s jump right in.

We lead off with a few acquisitions this week. Gilead Sciences is acquiring Tubulis, a German company that develops ADCs. Neurocrine Biosciences is buying out Soleno Therapeutics at a stock price worth nearly $3 billion. And Vion Biosciences has acquired Cellular Technology Limited, which provides immune monitoring services and software.

In pharma collaborations, Lilly and AC Immune are amending their 2018 R&D agreement for Tau aggregation inhibitor small molecules to potentially treat Alzheimer’s and other neurodegenerative diseases. Touchlight and SVF Vaccines have partnered to advance a hepatitis B/D vaccine into clinical development; this leverages a proprietary platform based on what’s called doggybone DNA.

Cartherics and Catalent are expanding their partnership to manufacture and commercialize iPSC-derived CAR-NK cell therapies. Akari Therapeutics and Wuxi XDC are accelerating development of a novel PH1 payload, initially targeted for urothelial cancer. Halozyme and Vertex are collaborating to license up to three drug targets. And in the Asia-Pacific region, Daiichi Sankyo and ATLATL have a new R&D agreement.

A few companies are making internal moves this week. Allucent is expanding its CRO focus across oncology, neuroscience, cell and gene therapy, and other areas. Scinai Immunotherapeutics has completed a corporate reorganization separating its CDMO and R&D operations. Meanwhile, Ofichem is bringing its CDMO and pharma brands under a single identity.

That should be plenty to entice you to read the rest of our coverage from a very busy week in the industry, which you can do anytime at contractpharma.com.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics